Evidence map›Paper›PMID 27228299›Full record

Trial reportBritish journal of cancer2016

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.

Michael J Sorich, Andrew Rowland, Ganessan Kichenadasse, Richard J Woodman, Arduino A Mangoni

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael J SorichDepartment of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia.
Andrew RowlandDepartment of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia.
Ganessan KichenadasseFlinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia.
Richard J WoodmanFlinders Centre for Epidemiology and Biostatistics, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia.
Arduino A MangoniDepartment of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide, South Australia 5042, Australia.
Flinders University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProteinuria is a common adverse effect of vascular endothelial growth factor targeted agents, particularly in metastatic renal cell carcinoma (mRCC). However, risk factors for proteinuria are poorly defined.

methodsData on 1392 mRCC patients using pazopanib or sunitinib were pooled from two Phase-III clinical trials. Risk factors and prognostic effect of on-therapy proteinuria were evaluated by Cox proportional hazards regression.

resultsAny-grade (1-4) and grade 3/4 proteinuria incidence were 15.0% and 3.7%, respectively. Asian ethnicity, diabetes, baseline systolic blood pressure (SBP), pre-existing grade 1 proteinuria and prior nephrectomy were significant independent predictors of either any-grade or grade 3/4 proteinuria. Proteinuria, particularly grade 3/4 (adjusted hazard ratio 0.53 (95% confidence interval 0.30-0.92)), was associated with improved overall survival.

conclusionsIn mRCC patients using pazopanib or sunitinib, Asian ethnicity, diabetes, SBP, pre-existing proteinuria and prior nephrectomy were independent predictors of on-therapy proteinuria, which was associated with improved survival.

Indexed as

Carcinoma, Renal CellFemaleHumansIndazolesIndolesKidney NeoplasmsMaleMiddle AgedProportional Hazards ModelsProteinuriaPyrimidinesPyrrolesRisk FactorsSulfonamidesSunitinibSurvival AnalysisIndazolesIndolespazopanibPyrimidinesPyrrolesSulfonamidesSunitinibVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID27228299
PMCPMC4984472
OpenAlexW2398989175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.